Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

About this update from Defence Therapeutics Inc Class A

Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations. Dr. Beaver has held senior leadership positions at several leading biopharmaceutical companies, including Biogen, AbbVie, and GlaxoSmithKline, where he contributed to the advancement of innovative therapeutic programs across multiple disease areas. His extensive experience spans translational medicine, biomarker discovery and development, and clinical pharmacology, providing him with a deep understanding of how innovative therapeutics are advanced, evaluated, and strategically developed within global pharma organizations. Most recently, Dr. Beaver served as Vice President and Head of Global Biomarker Discovery & Development at Biogen, where he led global biomarker and translational development activities supporting approximately 48 pipeline programs. During his tenure, he contributed to biomarker-driven development strategies associated with industry-first FDA accelerated approvals in Alzheimer's disease and ALS, while also serving on several R&D leadership, governance, and partnership committees. Prior to Biogen, Dr. Beaver held senior leadership roles at AbbVie, where he served as Head of Translational Imaging and was recognized as a Volwiler Research Fellow for his scientific contributions. Earlier in his career, he was a Senior Imaging Scientist at GlaxoSmithKline's Clinical Imaging Centre at Imperial College London's Hammersmith Hospital campus and later served as Director of Imaging at Maccine in Singapore. He also conducted human brain imaging research as a postdoctoral fellow with the UK Medical Research Council at the University of Cambridge. Dr. Beaver is currently the Co-Founder and Chief Executive Officer of a stealth-mode biotechnology company based in the Greater Boston area, where he is leveraging his extensive experience in translational science, biomarker innovation, and strategic drug development to advance next-generation therapeutic approaches. "We are ve...

View stock analysis, news, and events for Defence Therapeutics Inc Class A